
    
      This is a prospective, multicenter phase II trial designed to determine efficacy and safety
      of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with
      advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).

      The study includes and induction phase and a consolidation phase.
    
  